Post-earnings recap
Reported
Wed, Aug 9, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Axovant Gene Therapies reported a loss per share of $0.30, but did not provide revenue figures or guidance. The stock fell by 1.68% following the announcement, reflecting investor concerns about the lack of financial clarity and future direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.30 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management acknowledged the difficulties faced during the quarter. They emphasized their commitment to advancing clinical programs.
We are focused on advancing our clinical programs despite the challenges.
Our team remains committed to delivering value through our pipeline.